BOTOX Injections (cont.)
Authors and Editors
Author: Joel Schlessinger, MD, Consulting Staff, Dermatology, Skin Specialists, PC.
Editor: William C. Shiel Jr., MD, FACP, FACR
Previous contributing editors:
Editors: Dirk M Elston, MD, Consulting Staff, Department of Dermatology, Geisinger Medical Center; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; William D James, MD, Program Director, Vice-Chair, Paul R Gross Professor, Department of Dermatology, University of Pennsylvania School of Medicine.
REFERENCES: Last Editorial Review: 7/17/2012
About Botox Cosmetic. <http://www.botoxcosmetic.com/About_Botox.aspx>.
Antonucci , Flavia, et al. "Long-Distance Retrograde Effects of Botulinum Neurotoxin A."
The Journal of Neuroscience 28.14 Apr. 2, 2008: 3689-3696; doi: 10.1523/JNEUROSCI.0375-08.2008.
Cohen, J.L., J. Schlessinger, S.E. Cox, X. Lin; Reloxin Investigational Group. "An analysis of the long-term safety data of repeat administrations of botulinum neurotoxin type A-ABO for the treatment of glabellar lines."
Aesthet Surg J. 29.6 Nov. 2009: S43-49.
"Medication Guide: Botox." Allergan.com. <http://www.allergan.com/assets/pdf/botox_med_guide.pdf>.
Schlessinger, Joel, G. Monheit, M.A. Kane, and N. Mendelsohn. "Time to onset of Response of Abobotulinumtoxin A in the Treatment of Glabellar Lines: A Subset analysis of Phase 3 Clinical Trials of a New Botulinum Toxin Type A."
Dermatol Surgl. 37.10 Oct. 2011: 1434-1442. [Published on-line. July 11, 2011|001:10.1111/j.1524-4725.2011.02075.x]
Schlessinger, Joel, J. Kenkel, and P. Werschler. "Further Enhancement of Facial Appearance With a Hydroquinone Skin Care System Plus Tretinoin in Patients Previously Treated With Botulinum Toxin Type A."
Aesthet Surg J. 31.5 July 2011: 529-539.